We are live on ! Find out more
COLL icon

Collegium Pharmaceutical

228 hedge funds and large institutions have $1.54B invested in Collegium Pharmaceutical in 2024 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 78 increasing their positions, 78 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

453% more call options, than puts

Call options by funds: $3.33M | Put options by funds: $601K

225% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 16

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

24% more capital invested

Capital invested by funds: $1.24B → $1.54B (+$300M)

18% more funds holding

Funds holding: 193228 (+35)

0.71% more ownership

Funds ownership: 123.34%124.05% (+0.71%)

0% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 78

Holders
228
Holders Change
+35
Holders Change %
+18.13%
% of All Funds
3.28%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
52
Increased
78
Reduced
78
Closed
16
Calls
$3.33M
Puts
$601K
Net Calls
+$2.73M
Net Calls Change
+$4.57M
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$11.9M -$526K -15,021 -5%
RA
27
Royce & Associates
New York
$11.2M +$5.09M +145,626 +102%
Arrowstreet Capital
28
Arrowstreet Capital
Massachusetts
$10.8M +$2.07M +59,165 +27%
Loomis, Sayles & Company
29
Loomis, Sayles & Company
Massachusetts
$10.6M -$146K -4,177 -2%
Two Sigma Advisers
30
Two Sigma Advisers
New York
$10.4M +$794K +22,700 +9%
Man Group
31
Man Group
United Kingdom
$10.1M +$7.17M +204,957 +366%
BNP Paribas Financial Markets
32
BNP Paribas Financial Markets
France
$9.81M +$3.72M +106,203 +72%
PCM
33
Penn Capital Management
Pennsylvania
$9.53M -$2.49M -71,258 -23%
Two Sigma Investments
34
Two Sigma Investments
New York
$8.77M -$1.19M -34,006 -13%
BGIM
35
Brandywine Global Investment Management
Pennsylvania
$8.01M -$5.87M -167,701 -45%
D.E. Shaw & Co
36
D.E. Shaw & Co
New York
$7.73M -$782K -22,356 -10%
Bank of America
37
Bank of America
North Carolina
$7.71M +$6.3M +179,952 +970%
Millennium Management
38
Millennium Management
New York
$7.51M -$8.76M -250,274 -56%
QC
39
Quantedge Capital
Singapore
$6.69M +$6.03M +172,300 New
Goldman Sachs
40
Goldman Sachs
New York
$6.36M -$1.44M -41,112 -20%
SDIC
41
South Dakota Investment Council
South Dakota
$6.13M -$3.01M -85,946 -35%
New York State Common Retirement Fund
42
New York State Common Retirement Fund
New York
$6.07M -$1.57M -44,796 -22%
UIC
43
Uniplan Investment Counsel
Wisconsin
$5.7M -$6.12K -175 -0.1%
AllianceBernstein
44
AllianceBernstein
Tennessee
$5.08M -$1.02M -29,040 -18%
JP Morgan Chase
45
JP Morgan Chase
New York
$4.87M -$3.51M -100,392 -44%
Citadel Advisors
46
Citadel Advisors
Florida
$4.38M +$78.2K +2,235 +2%
HIM
47
Hillsdale Investment Management
Ontario, Canada
$4.33M +$602K +17,200 +18%
LPL Financial
48
LPL Financial
California
$4.26M -$353K -10,092 -8%
AQR Capital Management
49
AQR Capital Management
Connecticut
$4.24M +$139K +3,960 +4%
TI
50
Trexquant Investment
Connecticut
$4.2M +$478K +13,650 +14%

COLL Hedge Fund Activity: Q1 2024 in Review

228 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q1 2024, worth a combined $1.54B — up 24% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new COLL positions and 16 closed out — a net gain of 36 holders — while 78 added to existing stakes and 78 trimmed.

The largest buyer was Fuller & Thaler Asset Management, opening a new position worth an estimated $33.9M. The largest seller was Morgan Stanley, cutting an estimated $40.8M.

  • 228 institutional investors held Collegium Pharmaceutical (COLL) as of Q1 2024, up from 193 in Q4 2023.
  • Funds reported $1.54B of Collegium Pharmaceutical stock for Q1 2024, up 24% quarter-over-quarter.
  • 52 funds opened new Collegium Pharmaceutical positions in Q1 2024 and 16 closed out, a net change of +36 holders.
  • The largest Collegium Pharmaceutical buyer in Q1 2024 was Fuller & Thaler Asset Management, an estimated $33.9M added.
  • The largest Collegium Pharmaceutical seller in Q1 2024 was Morgan Stanley, an estimated $40.8M sold.

Based on aggregated 13F filings for Q1 2024.